Tetra Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cognitive impairment and memory loss associated with conditions such as Fragile X Syndrome and Alzheimer’s disease. The company’s primary investigational drug, BPN14770, selectively targets and inhibits the phosphodiesterase 4D (PDE4D) enzyme, which plays a crucial role in cognitive function. By modulating the activity of PDE4D, BPN14770 aims to enhance the maturation and stabilization of neuronal connections, thereby improving memory formation and cognitive abilities. This targeted approach is designed to minimize side effects commonly associated with broader PDE4 inhibitors, potentially offering a well-tolerated treatment option for patients.

In addition to BPN14770, Tetra Therapeutics is also exploring the role of phosphodiesterase 4B (PDE4B) in treating cognitive impairment resulting from traumatic brain injury. The company’s research indicates that inhibiting PDE4B can reduce inflammation in the brain, which is critical for restoring healthy brain function post-injury. Tetra’s drug discovery platform is not limited to neurological disorders; it also aims to develop treatments for various peripheral diseases where phosphodiesterases are relevant targets. Overall, Tetra Therapeutics is committed to advancing medical progress through its innovative pipeline, which seeks to address significant unmet medical needs in cognitive health.

United States

Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products. Tetra designs drugs to treat memory loss and cognitive impairment by improving how the brain processes and stores information. The company is focused on treating cognitive impairment and memory loss by improving brain function.

Tetra Therapeutics

Company Details